Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Status: | Recruiting |
---|---|
Conditions: | Prostate Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 10/26/2018 |
Start Date: | December 28, 2016 |
End Date: | March 1, 2020 |
Contact: | Mike Wheeler |
Email: | hcc-clinical-trials@musc.edu |
Phone: | 843-792-9321 |
Randomized Phase II Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
The purpose of this study is to look at the effect that the study drug OPC has on AGE levels
in patients with prostate cancer.
in patients with prostate cancer.
AGEs are a type of metabolite, or substance, found in the food. The AGE content in food is
determined by the types of food you eat and also how you prepare your food. The researchers
helping conduct this study have found a potential link between AGE levels and cancer. The
purpose of this study is to see if Oligomeric Procyanidin Complex (OPC) has an effect on the
AGE levels in your blood and to see if those AGE levels have an effect on your cancer.
determined by the types of food you eat and also how you prepare your food. The researchers
helping conduct this study have found a potential link between AGE levels and cancer. The
purpose of this study is to see if Oligomeric Procyanidin Complex (OPC) has an effect on the
AGE levels in your blood and to see if those AGE levels have an effect on your cancer.
Inclusion Criteria
1. Confirmation of adenocarcinoma of the prostate that is documented by one of the
following: pathology report or clinic note with documented history of prostate cancer.
2. Subjects must be receiving ADT with a GnRH agonist or antagonist, with or without an
anti-androgen, with a current testosterone level documented to be <50ng/dL at
enrollment. Subjects whose ADT is interrupted may enroll or continue on study as long
as the testosterone is documented to remain <50ng/dL for the entire duration of study
participation. Subjects who have undergone orchiectomy are also eligible.
3. Prior cytotoxic chemotherapy for metastatic prostate cancer; prior treatment with
genomically-targeted agents, or Provenge is allowed.
4. Subjects must have adequate hematologic, renal, and hepatic function at baseline, as
follows:
- Hematology parameters: ANC >1000/mcL, platelets > 100,000/mcL, Hgb >8.0gm/dL
- Renal Function: eGFR of > 45mls/min using Cockkroft and Gault formula (see
appendix C).
- Liver Function: Total bilirubin ≤ULN, AST and ALT <1.5xULN
5. Able to swallow and retain oral medication
6. ECOG performance status of 0 - 2
7. Ability to sign written informed consent
8. Testosterone level <50ng/dL
Exclusion Criteria
1. Known allergy to grapes or grape seed
2. History of receiving more than 2 classes of ADT.
3. Current use of strong antioxidants (extracts from grape seed, milk thistle; pine bark,
green tea, saw palmetto; resveratrol; flavonoids; catechins; ellagic acid), large
quantities of red grapes, white button mushrooms, red wine. See section 4.7 for more
details.
4. PSA doubling time of <6 months, measured over the 3 months prior to enrollment.
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials